Completed PHASE4 INTERVENTIONAL 3-arm NCT03608761

Comparison Between Rebamipide 2% Versus Autologous Serum

Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study

Sponsor: Hospital Nacional Profesor Alejandro Posadas

Conditions Dry Eye Syndromes Sjögren Syndrome

Interventions Rebamipide autologous serum autologous serum and rebamipide 2%

Updated 5 times since 2018 Last updated: Dec 2, 2018 Started: Feb 6, 2017 Primary completion: Oct 9, 2017 Completion: Jul 9, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Dry Eye Syndromes and Sjögren Syndrome, this trial is completed. The trial is conducted by Hospital Nacional Profesor Alejandro Posadas and has accumulated 5 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2019 — Jan 2021 [monthly]

Completed PHASE4
Aug 2018 — Jan 2019 [monthly]

Completed PHASE4

First recorded

Feb 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Nacional Profesor Alejandro Posadas

Data source: Hospital Nacional Profesor Alejandro Posadas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• El Palomar, Argentina